The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

[1]  J. Krueger,et al.  In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. , 2021, The Journal of investigative dermatology.

[2]  G. Fabbrocini,et al.  Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  E. Prens,et al.  Drug survival of Adalimumab and Infliximab in Hidradenitis Suppurativa Patients: A Daily Practice Cohort Study , 2021 .

[4]  J. Krueger,et al.  Epithelialized Tunnels are a Source of Inflammation in Hidradenitis Suppurativa. , 2021, The Journal of allergy and clinical immunology.

[5]  J. Szepietowski,et al.  Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1,795 Patients , 2020, Acta dermato-venereologica.

[6]  V. Piguet,et al.  A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. , 2020, The Journal of investigative dermatology.

[7]  Kathleen M. Smith,et al.  Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy , 2020, JCI insight.

[8]  T. Agner,et al.  Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers , 2020, Frontiers in Immunology.

[9]  J. Krueger,et al.  Doppler ultrasound‐based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity , 2020, The British journal of dermatology.

[10]  J. Krueger,et al.  The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study. , 2020, Journal of the American Academy of Dermatology.

[11]  Z. Reguiaï,et al.  Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  G. Singer,et al.  Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. , 2020, Journal of the American Academy of Dermatology.

[13]  T. Montero-Vílchez,et al.  The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review , 2020, Dermatologic therapy.

[14]  P. Proost,et al.  Neutrophil chemoattractant receptors in health and disease: double-edged swords , 2020, Cellular & Molecular Immunology.

[15]  B. Kirby,et al.  Successful use of guselkumab in the treatment of severe hidradenitis suppurativa , 2020, Clinical and experimental dermatology.

[16]  A. Gottlieb,et al.  Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial. , 2020, Journal of the American Academy of Dermatology.

[17]  H. Hosgood,et al.  High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. , 2020, Journal of the American Academy of Dermatology.

[18]  J. Krueger,et al.  Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa , 2020, The British journal of dermatology.

[19]  J. Krueger,et al.  The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. , 2020, Journal of the American Academy of Dermatology.

[20]  J. Kirby,et al.  Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies , 2019, The British journal of dermatology.

[21]  A. Gottlieb,et al.  Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa , 2019, The British journal of dermatology.

[22]  M. Lowes,et al.  A Call to Accelerate Hidradenitis Suppurativa Research and Improve Care-Moving Beyond Burden. , 2019, JAMA dermatology.

[23]  R. Schmid,et al.  Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. , 2019, The Journal of allergy and clinical immunology.

[24]  T. Lingner,et al.  The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. , 2019, The Journal of investigative dermatology.

[25]  M. Podda,et al.  Guselkumab in the treatment of severe hidradenitis suppurativa , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  A. Vossen,et al.  Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  L. Tsoi,et al.  Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch , 2018, Allergy.

[28]  C. Zouboulis,et al.  Long‐term adalimumab efficacy in patients with moderate‐to‐severe hidradenitis suppurativa/acne inversa: 3‐year results of a phase 3 open‐label extension study , 2019, Journal of the American Academy of Dermatology.

[29]  K. Kridin,et al.  Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study. , 2018, Journal of the American Academy of Dermatology.

[30]  M. Suárez-Fariñas,et al.  Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature , 2018, PloS one.

[31]  M. Teixeira,et al.  Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders , 2018, Front. Psychiatry.

[32]  J. Szepietowski,et al.  Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa. , 2018, Acta dermato-venereologica.

[33]  B. Moran,et al.  Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. , 2017, The Journal of investigative dermatology.

[34]  E. Berti,et al.  Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis) , 2017, The British journal of dermatology.

[35]  A. Banerjee,et al.  Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa , 2017, Immunological investigations.

[36]  Y. Lévy,et al.  Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. , 2016, The Journal of investigative dermatology.

[37]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.

[38]  B. Malissen,et al.  CD6 modulates thymocyte selection and peripheral T cell homeostasis , 2016, The Journal of experimental medicine.

[39]  S. Tian,et al.  Increased expression of interleukin‐17 pathway genes in nonlesional skin of moderate‐to‐severe psoriasis vulgaris , 2016, The British journal of dermatology.

[40]  M. Netea,et al.  Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. , 2016, JAMA dermatology.

[41]  C. Sweeney,et al.  Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa , 2015, The British journal of dermatology.

[42]  R. Verhaak,et al.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. , 2015, Cancer research.

[43]  E. Ingelsson,et al.  Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. , 2015, Atherosclerosis.

[44]  Kristi Abram,et al.  Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN , 2015, BMC Genomics.

[45]  Yi Dai,et al.  Peripherally increased artemin is a key regulator of TRPA1/V1 expression in primary afferent neurons , 2015, Molecular pain.

[46]  Y. Chun,et al.  Keratinocyte-derived IL-24 plays a role in the positive feedback regulation of epidermal inflammation in response to environmental and endogenous toxic stressors. , 2014, Toxicology and applied pharmacology.

[47]  L. Burkly.  TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities. , 2014, Seminars in immunology.

[48]  M. Rosenblum,et al.  An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. , 2014, Journal of the American Academy of Dermatology.

[49]  M. Gold,et al.  Artemin growth factor increases nicotinic cholinergic receptor subunit expression and activity in nociceptive sensory neurons , 2014, Molecular pain.

[50]  Youping Deng,et al.  HGF Accelerates Wound Healing by Promoting the Dedifferentiation of Epidermal Cells through β 1-Integrin/ILK Pathway , 2013, BioMed research international.

[51]  H. Murota,et al.  Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[52]  J. Laman,et al.  Adalimumab (antitumour necrosis factor‐α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study , 2012, The British journal of dermatology.

[53]  N. Yawalkar,et al.  Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. , 2011, Journal of the American Academy of Dermatology.

[54]  J. Laman,et al.  Elevated levels of tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β and IL‐10 in hidradenitis suppurativa skin: a rationale for targeting TNF‐α and IL‐1β , 2011, The British journal of dermatology.

[55]  H. Volk,et al.  Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa , 2011, The Journal of Immunology.

[56]  A. Caudle,et al.  IL‐24 is expressed during wound repair and inhibits TGFα‐induced migration and proliferation of keratinocytes , 2009, Experimental dermatology.

[57]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[58]  D. Groneberg,et al.  High abundances of neurotrophin 3 in atopic dermatitis mast cell , 2009, Journal of occupational medicine and toxicology.

[59]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[60]  E. Riley,et al.  IL-10: The Master Regulator of Immunity to Infection , 2008, The Journal of Immunology.

[61]  J. Klarlund,et al.  Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. , 2007, Experimental cell research.

[62]  H. Koerber,et al.  Artemin Overexpression in Skin Enhances Expression of TRPV1 and TRPA1 in Cutaneous Sensory Neurons and Leads to Behavioral Sensitivity to Heat and Cold , 2006, The Journal of Neuroscience.

[63]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[64]  T. Hla,et al.  TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[65]  S. Mitsui,et al.  Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in in vitro HGF-dependent hair follicle elongation. , 2001, Journal of dermatological science.

[66]  Lieping Chen,et al.  LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1 , 2000, The Journal of Immunology.

[67]  P. Anand,et al.  Neurotrophin-3 is increased in skin in human diabetic neuropathy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[68]  K. Tashiro,et al.  Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.